These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 31831554)

  • 1. A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin.
    Arena S; Corti G; Durinikova E; Montone M; Reilly NM; Russo M; Lorenzato A; Arcella P; Lazzari L; Rospo G; Pagani M; Cancelliere C; Negrino C; Isella C; Bartolini A; Cassingena A; Amatu A; Mauri G; Sartore-Bianchi A; Mittica G; Medico E; Marsoni S; Linnebacher M; Abrignani S; Siena S; Di Nicolantonio F; Bardelli A
    Clin Cancer Res; 2020 Mar; 26(6):1372-1384. PubMed ID: 31831554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual inhibition of VEGF and PARP suppresses KRAS-mutant colorectal cancer.
    Zhong L; Wang R; Wang Y; Peng S; Ma Y; Ding S; Yang H; Chen S; Luo X; Wang W
    Neoplasia; 2020 Sep; 22(9):365-375. PubMed ID: 32629177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PARP-1 activity (PAR) determines the sensitivity of cervical cancer to olaparib.
    Bianchi A; Lopez S; Altwerger G; Bellone S; Bonazzoli E; Zammataro L; Manzano A; Manara P; Perrone E; Zeybek B; Han C; Menderes G; Ratner E; Silasi DA; Huang GS; Azodi M; Newberg JY; Pavlick DC; Elvin J; Frampton GM; Schwartz PE; Santin AD
    Gynecol Oncol; 2019 Oct; 155(1):144-150. PubMed ID: 31434613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In silico screening identifies a novel small molecule inhibitor that counteracts PARP inhibitor resistance in ovarian cancer.
    Lin ZP; Al Zouabi NN; Xu ML; Bowen NE; Wu TL; Lavi ES; Huang PH; Zhu YL; Kim B; Ratner ES
    Sci Rep; 2021 Apr; 11(1):8042. PubMed ID: 33850183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer.
    Li L; Karanika S; Yang G; Wang J; Park S; Broom BM; Manyam GC; Wu W; Luo Y; Basourakos S; Song JH; Gallick GE; Karantanos T; Korentzelos D; Azad AK; Kim J; Corn PG; Aparicio AM; Logothetis CJ; Troncoso P; Heffernan T; Toniatti C; Lee HS; Lee JS; Zuo X; Chang W; Yin J; Thompson TC
    Sci Signal; 2017 May; 10(480):. PubMed ID: 28536297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Onvansertib treatment overcomes olaparib resistance in high-grade ovarian carcinomas.
    Chiappa M; Decio A; Guarrera L; Mengoli I; Karki A; Yemane D; Ghilardi C; Scanziani E; Canesi S; Barbera MC; Craparotta I; Bolis M; Fruscio R; Grasselli C; Ceruti T; Zucchetti M; Patterson JC; Lu RA; Yaffe MB; Ridinger M; Damia G; Guffanti F
    Cell Death Dis; 2024 Jul; 15(7):521. PubMed ID: 39039067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Indenoisoquinoline TOP1 Inhibitors Selectively Target Homologous Recombination-Deficient and Schlafen 11-Positive Cancer Cells and Synergize with Olaparib.
    Marzi L; Szabova L; Gordon M; Weaver Ohler Z; Sharan SK; Beshiri ML; Etemadi M; Murai J; Kelly K; Pommier Y
    Clin Cancer Res; 2019 Oct; 25(20):6206-6216. PubMed ID: 31409613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRISPR screens identify a novel combination treatment targeting BCL-X
    Jung HR; Oh Y; Na D; Min S; Kang J; Jang D; Shin S; Kim J; Lee SE; Jeong EM; An JY; Sung CO; Lee WS; Lee C; Cho SY
    Oncogene; 2021 May; 40(18):3287-3302. PubMed ID: 33846570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin.
    Ordóñez JL; Amaral AT; Carcaboso AM; Herrero-Martín D; del Carmen García-Macías M; Sevillano V; Alonso D; Pascual-Pasto G; San-Segundo L; Vila-Ubach M; Rodrigues T; Fraile S; Teodosio C; Mayo-Iscar A; Aracil M; Galmarini CM; Tirado OM; Mora J; de Álava E
    Oncotarget; 2015 Aug; 6(22):18875-90. PubMed ID: 26056084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ATF3-induced activation of NF-κB pathway results in acquired PARP inhibitor resistance in pancreatic adenocarcinoma.
    Liu Y; Cao Y; Liu P; Zhai S; Liu Y; Tang X; Lin J; Shi M; Qi D; Deng X; Zhu Y; Wang W; Shen B
    Cell Oncol (Dordr); 2024 Jun; 47(3):939-950. PubMed ID: 38097870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CDK inhibition results in pharmacologic BRCAness increasing sensitivity to olaparib in BRCA1-WT and olaparib resistant in Triple Negative Breast Cancer.
    Orhan E; Velazquez C; Tabet I; Fenou L; Rodier G; Orsetti B; Jacot W; Sardet C; Theillet C
    Cancer Lett; 2024 May; 589():216820. PubMed ID: 38574883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro.
    Patel AG; De Lorenzo SB; Flatten KS; Poirier GG; Kaufmann SH
    Clin Cancer Res; 2012 Mar; 18(6):1655-62. PubMed ID: 22291137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolism-focused CRISPR screen unveils mitochondrial pyruvate carrier 1 as a critical driver for PARP inhibitor resistance in lung cancer.
    Furusawa T; Cavero R; Liu Y; Li H; Xu X; Andresson T; Reinhold W; White O; Boufraqech M; Meyer TJ; Hartmann O; Diefenbacher ME; Pommier Y; Weyemi U
    Mol Carcinog; 2024 Jun; 63(6):1024-1037. PubMed ID: 38411275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activated NAD+ biosynthesis pathway induces olaparib resistance in BRCA1 knockout pancreatic cancer cells.
    Sasaki Y; Inouchi T; Nakatsuka R; Inoue A; Masutani M; Nozaki T
    PLoS One; 2024; 19(4):e0302130. PubMed ID: 38625917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liensinine sensitizes colorectal cancer cells to oxaliplatin by targeting HIF-1α to inhibit autophagy.
    Feng Z; Zhang S; Han Q; Chu T; Wang H; Yu L; Zhang W; Liu J; Liang W; Xue J; Wu X; Zhang C; Wang Y
    Phytomedicine; 2024 Jul; 129():155647. PubMed ID: 38703660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Promising Response of Olaparib in Patient With Germline
    Chan KH; Rutazanaa D; Wray C; Thosani N; Yang V; Cen P
    J Investig Med High Impact Case Rep; 2024; 12():23247096241240176. PubMed ID: 38504422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical efficacy of carfilzomib in BRAF-mutant colorectal cancer models.
    Maione F; Oddo D; Galvagno F; Falcomatà C; Pandini M; Macagno M; Pessei V; Barault L; Gigliotti C; Mira A; Corti G; Lamba S; Riganti C; Castella B; Massaia M; Rad R; Saur D; Bardelli A; Di Nicolantonio F
    Mol Oncol; 2024 Jun; 18(6):1552-1570. PubMed ID: 38348572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ketogenesis attenuated KLF5 disrupts iron homeostasis via LIF to confer oxaliplatin vulnerability in colorectal cancer.
    Jiang H; Zeng Y; Jiang X; Xu X; Zhao L; Yuan X; Xu J; Zhao M; Wu F; Li G
    Biochim Biophys Acta Mol Basis Dis; 2024 Aug; 1870(6):167210. PubMed ID: 38704001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting SMAD3 Improves Response to Oxaliplatin in Esophageal Adenocarcinoma Models by Impeding DNA Repair.
    Ballout F; Lu H; Bhat N; Chen L; Peng D; Chen Z; Chen S; Sun X; Giordano S; Corso S; Zaika A; McDonald O; Livingstone AS; El-Rifai W
    Clin Cancer Res; 2024 May; 30(10):2193-2205. PubMed ID: 38592373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RNA-seq identifies determinants of oxaliplatin sensitivity in colorectal cancer cell lines.
    Li XX; Peng JJ; Liang L; Huang LY; Li DW; Shi DB; Zheng HT; Cai SJ
    Int J Clin Exp Pathol; 2014; 7(7):3763-70. PubMed ID: 25120752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.